Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate

American Journal of Cardiovascular Drugs

Volumn 7, Issue 5, 2007, Pages 361-372

  Kereiakes, Dean J ^a   Neutel, Joel M ^b   Punzi, Henry A ^c,d   Xu, Jianbo ^e   Lipka, Leslie J ^f   Dubiel, Robert ^e  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b Orange County   (United States)

^c Trinity Hypertension Research Institute   (United States)

^d TEXAS WOMAN'S UNIVERSITY   (United States)

^e DAIICHI SANKYO INC   (United States)

^f FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Amlodipine, therapeutic use; Benazepril, therapeutic use; Hypertension, treatment; Olmesartan medoxomil hydrochlorothiazide, therapeutic use

Indexed keywords

AMLODIPINE BESYLATE; BENAZEPRIL; HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO;

ADULT; AMBULATORY MONITORING; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIVERTICULITIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; HUMAN; LEG EDEMA; LIMB PAIN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SAMPLE SIZE; SIDE EFFECT; SINUSITIS; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THERAPY EFFECT; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 35448989395     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707050-00006     Document Type: Article

References (29)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13
3. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62
4. Cheung BM, Ong KL, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich) 2006; 8: 93-8
5. Ong KL, Cheung BMY, Man YB et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75
6. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536
7. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92
8. Campbell M, Sonkodi S, Soucek M, et al. A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clin Exp Hypertens 2001; 23: 345-55
9. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17: 252-9
10. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797-805
11. Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27: 1013-21
12. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833-50
13. Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001; 15: 495-8
14. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425-32
15. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283-91, 318
16. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 Suppl. 2: S24-8
17. Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs 2006; 6: 103-13
18. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 2001; 37: 12-8
19. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
20. Andros V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm 2006; 12: 303-9
21. Brindel P, Hanon O, Dartigues JF, et al. Prevalence, awareness, treatment, and control of hypertension in the elderly: the Three City study. J Hypertens 2006; 24: 51-8
22. Mancia G, Pessina AC, Trimarco B, et al. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22: 2387-96
23. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens 2004; 17: 590-6
24. Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995; 35: 1060-6
25. Malacco E, Piazza S, Carretta R, et al. Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. Int J Clin Pharmacol Ther 2002; 40: 263-9
26. Bakris GL, Weir MR. Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003; 5: 202-9
27. Neutel JM, Smith DH, Weber MA, et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004; 6: 168-74
28. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41-50
29. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 169S-73S